These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 33789011)

  • 21. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
    Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH
    Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
    Muensterman E; Engelhardt B; Gopalakrishnan S; Anderson JK; Mohamed MF
    Clin Transl Sci; 2022 Jan; 15(1):267-278. PubMed ID: 34464029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of upadacitinib in the treatment of psoriatic arthritis.
    Ross Y; Magrey M
    Immunotherapy; 2021 Dec; 13(18):1549-1554. PubMed ID: 34645316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
    Fleischmann RM; Blanco R; Hall S; Thomson GTD; Van den Bosch FE; Zerbini C; Bessette L; Enejosa J; Li Y; Song Y; DeMasi R; Song IH
    Ann Rheum Dis; 2021 Apr; 80(4):432-439. PubMed ID: 33148701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E; Thaçi D; Pangan AL; Hong HC; Papp KA; Reich K; Beck LA; Mohamed MF; Othman AA; Anderson JK; Gu Y; Teixeira HD; Silverberg JI
    J Allergy Clin Immunol; 2020 Mar; 145(3):877-884. PubMed ID: 31786154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
    Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
    Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
    Fleischmann R; Mysler E; Bessette L; Peterfy CG; Durez P; Tanaka Y; Swierkot J; Khan N; Bu X; Li Y; Song IH
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35121639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.